Este es el que agregas al carrito
Más información sobre el libro
The book presents a groundbreaking strategy for complete cancer treatment through two novel drug compounds, PT162 and PT167, developed by Andreas J. Kesel. These drugs target the Warburg effect, exploiting cancer's reliance on glycolysis due to mitochondrial dysfunction. Both compounds demonstrate significant efficacy in vitro against 60 cancer cell lines, inducing apoptosis by reactivating p53 and disrupting cyclin D1 regulation. The book details the chemistry behind these compounds and their apoptotic mechanisms, offering hope for innovative cancer therapies.
Compra de libros
THE POTENTIAL HEALING OF CANCER WITH P53 (RE)ACTIVATORS, Andreas Johannes Kesel
- Idioma
- Publicado en
- 2023
- Encuadernación
- (Tapa dura),
- Estado del libro
- Muy Bueno
- Precio
- 23,49 €
Métodos de pago
Nadie lo ha calificado todavía.
- Título
- THE POTENTIAL HEALING OF CANCER WITH P53 (RE)ACTIVATORS
- Subtítulo
- TWO NEW DRUGS EXPLOITING CANCER'S WARBURG EFFECT
- Idioma
- Inglés
- Autores
- Andreas Johannes Kesel
- Editorial
- tredition
- Publicado en
- 2023
- Formato
- Tapa dura
- Páginas
- 264
- ISBN10
- 3384003128
- ISBN13
- 9783384003126
- Serie
- Categorías
- Etiquetas
- No ficción, Salud & Medicina, Ciencia y Matemáticas, Naturaleza, Ciencias naturales, Medicina, Química, Farmacología, Bioquímica, Oncología, Química orgánica, Biología Molecular, Biología humana, Química Inorgánica, Quimioterapia, Farmacoterapia
- Descripción
- The book presents a groundbreaking strategy for complete cancer treatment through two novel drug compounds, PT162 and PT167, developed by Andreas J. Kesel. These drugs target the Warburg effect, exploiting cancer's reliance on glycolysis due to mitochondrial dysfunction. Both compounds demonstrate significant efficacy in vitro against 60 cancer cell lines, inducing apoptosis by reactivating p53 and disrupting cyclin D1 regulation. The book details the chemistry behind these compounds and their apoptotic mechanisms, offering hope for innovative cancer therapies.